RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Shares of Avidity Biosciences surged 36% in the past month following a Financial Times report indicating early-stage acquisition discussions with Novartis, though a deal is not guaranteed and other suitors could emerge. Novartis' reported interest in the clinical-stage RNA therapeutics developer, which specializes in novel treatments for rare muscular and cardiovascular diseases and holds partnerships with Bristol Myers and Eli Lilly, is seen as a strategic move to expand its pipeline and offset impending generic erosion of top-selling drugs like Entresto.

Analysis

Avidity Biosciences (RNA) shares have experienced a significant 36% increase over the past month, a rally directly attributed to a Financial Times report of potential acquisition interest from Novartis (NVS). This M&A speculation has driven Avidity's year-to-date performance to a 59% gain, starkly outperforming the broader industry's 4% growth. The strategic rationale for Novartis is clear: the company faces looming generic competition for key revenue drivers like Entresto and is actively pursuing bolt-on acquisitions to bolster its pipeline, as evidenced by recent deals for Anthos Therapeutics and Regulus Therapeutics. Acquiring Avidity would provide Novartis with a clinical-stage portfolio of novel RNA therapeutics targeting rare muscular diseases and an entry into precision cardiology, complementing its existing cardiovascular franchise. While Avidity's collaborations with Bristol Myers and Eli Lilly provide some validation and revenue ($3.8 million in Q2 2025), the acquisition discussions are reported to be at an early, non-guaranteed stage. This speculative optimism is contrasted by the stock's Zacks Rank #4 (Sell), suggesting a potential disconnect between the M&A-driven valuation and its underlying fundamentals.

Key Decisions for Investors

• Investors holding Avidity Biosciences should recognize that the stock's recent 36% appreciation is heavily predicated on M&A speculation, posing significant downside risk if a deal does not materialize or is priced below current expectations.
• For Novartis investors, the potential acquisition represents a positive strategic signal, demonstrating management's proactive approach to mitigating revenue loss from generic erosion by targeting high-value assets in the rare disease and cardiovascular space.
• Market participants should closely monitor for official confirmations or denials from either company, as well as any reports of other potential suitors, as these developments will be the primary near-term catalysts for Avidity's valuation, likely overshadowing the fundamentals reflected in its Zacks #4 'Sell' rating.